{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=BillionToOne+Inc.",
    "query": {
      "sponsor": "BillionToOne Inc."
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 3,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T16:20:35.397Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05733689",
      "title": "Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastroesophageal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "FLOT",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "FOLFOX",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "FOLFIRI",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "FOLFIRINOX",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "PACLITAXEL with or without CARBOPLATIN",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "DOCETAXEL and IRINOTECAN (alone or combined)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "NIVOLUMAB (alone or when added to a regimen above)",
          "type": "DRUG"
        },
        {
          "name": "PEMBROLIZUMAB (alone or when added to a regimen above)",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2025-06-27",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-03-10",
      "last_synced_at": "2026-09-28T16:20:35.397Z",
      "location_count": 1,
      "location_summary": "Orange, California",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05733689"
    },
    {
      "nct_id": "NCT07643896",
      "title": "The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pregnant Individuals",
        "Aneuploidy",
        "Down Syndrome (Trisomy 21)",
        "22q11.2 Deletion Syndrome",
        "Trisomy 13",
        "Trisomy 18",
        "Sex Chromosome Abnormalities"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "BillionToOne Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 1000,
      "start_date": "2026-01-10",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-09-28T16:20:35.397Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • West Covina, California • Sarasota, Florida + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "West Covina",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07643896"
    },
    {
      "nct_id": "NCT07096362",
      "title": "Utility of ctDNA in Early Switch of First-line Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Pancreatic Ductal Adenocarcinoma",
        "Pancreatic Ductal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "5-Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Nab Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2025-09-09",
      "completion_date": "2030-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-09-28T16:20:35.397Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07096362"
    }
  ]
}